Structure and Ligand-based design of P-glycoprotein inhibitors: A historical perspective

Current Pharmaceutical Design

Volumn 18, Issue 27, 2012, Pages 4197-4214

  Palmeira, Andreia ^a   Sousa, Emília ^a   Helena Vasconcelos, M ^a   Pinto, Madalena ^a   Fernandes, Miguel X ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MADEIRA   (Portugal)

Author keywords

Computer assisted drug design; Homology modeling; P glycoprotein inhibitors; Pharmacophore; Quantitative structure activity relationships; Structure based drug design

Indexed keywords

GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR;

BINDING SITE; COMPUTER ASSISTED DRUG DESIGN; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG STRUCTURE; HUMAN; METHODOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MICE; NEOPLASMS; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866309751     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802430530     Document Type: Review

References (133)

1. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-1972.
2. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166.
3. Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008; 73: 592-604.
4. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006; 580: 998-1009.
5. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds. Curr Med Chem 2012; 19(13):1946-2025.
6. Aller SG, Yu J, Ward A, Weng Y, et al. Structure of Pglycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-1722.
7. Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 2005; 280: 2857-2862.
8. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003; 278: 8294-8299.
9. Rosenberg MF, Velarde G, Ford RC, et al. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 2001; 20: 5615-5625.
10. Rosenberg MF, Callaghan R, Ford RC, Higgins CF. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 1997; 272: 10685-10694.
11. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol 1997; 8: 135-142.
12. Sharom FJ, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. Biochim Biophys Acta 1999; 1461: 327-345.
13. Hennessy M, Spiers JP. A primer on the mechanics of Pglycoprotein the multidrug transporter. Pharmacol Res 2007; 55: 1-15.
14. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009; 3: 281-290.
15. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 2007; 113: 429-441.
16. Demmer A, Dunn T, Hoof T, Kubesch P, Tummler B. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788. Eur J Pharmacol 1996; 315: 339-343.
17. Tamai I, Safa AR. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 1990; 265: 16509-16513.
18. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165.
19. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse Pglycoprotein. Proc Natl Acad Sci USA 1998; 95: 9831-9836.
20. Rothnie A, Storm J, McMahon R, Taylor A, Kerr ID, Callaghan R. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett 2005; 579: 3984-3990.
21. Maki N, Dey S. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1). Biochem Pharmacol 2006; 72: 145-155.
22. Maki N, Hafkemeyer P, Dey S. Allosteric modulation of human Pglycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 2003; 278: 18132-18139.
23. Malkhandi J, Ferry DR, Boer R, Gekeler V, Ise W, Kerr DJ. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 1994; 288: 105-114.
24. Ravna AW, Sylte I, Sager G. Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor Biol Med Model 2007; 4: 33.
25. Baker M. Making membrane proteins for structures: a trillion tiny tweaks. Nat Methods 2010; 7: 429-434.
26. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and unctions of P-glycoprotein. Curr Med Chem 2010; 17: 786-800.
27. Xu X, Fu J, Wang H, Zhang B, Wang X, Wang Y. Influence of Pglycoprotein on embryotoxicity of the antifouling biocides to sea urchin (Strongylocentrotus intermedius). Ecotoxicology 2010.
28. Jabeen I, Wetwitayaklung P, Klepsch F, Parveen Z, Chiba P, Ecker GF. Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines. Chem Commun (Camb) 2010.
29. Klepsch F, Chiba P, Ecker GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of p-glycoprotein. PLoS Comput Biol 2011; 7: e1002036.
30. Chang G. Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 2003; 330: 419-430.
31. Ravna AW, Sylte I, Sager G. Binding site of ABC transporter homology models confirmed by ABCB1 crystal structure. Theor Biol Med Model 2009; 6: 20.
32. Becker JP, Depret G, Van Bambeke F, Tulkens PM, Prevost M. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct Biol 2009; 9: 3.
33. Shilling RA, Venter H, Velamakanni S, et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 2006; 27: 195-203.
34. Pleban K, Kopp S, Csaszar E, Peer M, Hrebicek T, Rizzi A, Ecker GF, Chiba P. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol 2005; 67: 365-374.
35. Pajeva IK, Globisch C, Wiese M. Structure-function relationships of multidrug resistance P-glycoprotein. J Med Chem 2004; 47: 2523-2533.
36. Stenham DR, Campbell JD, Sansom MS, Higgins CF, Kerr ID, Linton KJ. An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide crosslinking and homology modeling. FASEB J 2003; 17: 2287-2289.
37. Seigneuret M, Garnier-Suillerot A. A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J Biol Chem 2003; 278: 30115-30124.
38. Qian F, Wei D, Zhang Q, Yang S. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother 2005; 59: 64-69.
39. Dawson RJ, Locher KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 2007; 581: 935-938.
40. Urry DW, Urry KD, Szaflarski W, Nowicki M, Zabel M. Function and frustration of multi-drug ABC exporter protein and design of model proteins for drug delivery using protein hydration thermodynamics. Curr Pharm Des 2009; 15: 2833-2867.
41. Velamakanni S, Yao Y, Gutmann DA, van Veen HW. Multidrug transport by the ABC transporter Sav1866 from Staphylococcus aureus. Biochemistry 2008; 47: 9300-9308.
42. Globisch C, Pajeva IK, Wiese M. Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMed-Chem 2008; 3: 280-295.
43. O'Mara ML, Tieleman DP. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett 2007; 581: 4217-4222.
44. Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto MM, Sousa E. Design of dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. 2011: 83(1):57-68.
45. Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 2002; 296: 1091-1098.
46. Diederichs K, Diez J, Greller G, Muller C, Breed J, Schnell C, Vonrhein C, Boos W, Welte W. Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis. EMBO J 2000; 19: 5951-5961.
47. Hung LW, Wang IX, Nikaido K, Liu PQ, Ames GF, Kim SH. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 1998; 396: 703-707.
48. Gaudet R, Wiley DC. Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing. EMBO J 2001; 20: 4964-4972.
49. Badhan R, Penny J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 2006; 41: 285-295.
50. Qian F, Wei D, Liu J, Yang S. Molecular model and ATPase activity of carboxyl-terminal nucleotide binding domain from human Pglycoprotein. Biochemistry (Mosc) 2006; 71 Suppl 1: S18-S24, 1-2.
51. Cornwell MM, Tsuruo T, Gottesman MM, Pastan I. ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. FASEB J 1987; 1: 51-54.
52. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-489.
53. Ohnuma S, Chufan E, Nandigama K, Jenkins LM, Durell SR, Appella E, Sauna ZE, Ambudkar SV. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an atp analogue that interacts with both drug-substrate-and nucleotide-binding sites. Biochemistry 2011; 50: 3724-3735.
54. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67-113.
55. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188-199.
56. Davidson AL, Dassa E, Orelle C, Chen J. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 2008; 72: 317-364, table of contents.
57. Neyfakh AA. Mystery of multidrug transporters: the answer can be simple. Mol Microbiol 2002; 44: 1123-1130.
58. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J 2003; 376: 313-338.
59. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci USA 2007; 104: 19005-19010.
60. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006; 443: 180-185.
61. Smith PC, Karpowich N, Millen L, Moody JE, Rosen J, Thomas PJ, Hunt JF. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 2002; 10: 139-149.
62. Zolnerciks JK, Wooding C, Linton KJ. Evidence for a Sav1866- like architecture for the human multidrug transporter Pglycoprotein. FASEB J 2007; 21: 3937-3948.
63. Pleban K, Kaiser D, Kopp S, Peer M, Chiba P, Ecker GF. Targeting drug-efflux pumps -- a pharmacoinformatic approach. Acta Biochim Pol 2005; 52: 737-740.
64. Andricopulo AD. Structure- and ligand-based drug design: advances and perspectives. Curr Top Med Chem 2009; 9: 754.
65. Seelig A, Landwojtowicz E. Structure-activity relationship of Pglycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40.
66. Dearden JC, Al-Noobi A, Scott AC, Thomson SA. QSAR studies on P-glycoprotein-regulated multidrug resistance and on its reversal by phenothiazines. SAR QSAR Environ Res 2003; 14: 447-454.
67. Kim KH. 3D-QSAR analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorg Med Chem 2001; 9: 1517-1523.
68. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in Pglycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem 2002; 45: 5671-5686.
69. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of Pglycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun 1988; 153: 959-966.
70. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988; 33: 454-462.
71. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 1989; 86: 5128-5132.
72. Nogae I, Kohno K, Kikuchi J, Kuwano M, Akiyama S, Kiue A, Suzuki K, Yoshida Y, Cornwell MM, Pastan I, et al. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of Pglycoprotein. Biochem Pharmacol 1989; 38: 519-527.
73. Ramu N, Ramu A. Circumvention of adriamycin resistance by dipyridamole analogues: a structure-activity relationship study. Int J Cancer 1989; 43: 487-491.
74. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989; 35: 105-115.
75. Pommerenke EW, Osswald H, Hahn EW, Volm M. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Lett 1990; 55: 17-23.
76. Thimmaiah KN, Horton JK, Qian XD, Beck WT, Houghton JA, Houghton PJ. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. Cancer Commun 1990; 2: 249-259.
77. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992; 30: 165-173.
78. Ramu A, Ramu N. Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds. Cancer Chemother Pharmacol 1994; 34: 423-430.
79. Dhainaut A, Regnier G, Atassi G, et al. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 1992; 35: 2481-2496.
80. Toffoli G, Simone F, Corona G, et al. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol 1995; 50: 1245-1255.
81. Bain LJ, McLachlan JB, LeBlanc GA. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 1997; 105: 812-818.
82. Suzuki T, Fukazawa N, San-nohe K, Sato W, Yano O, Tsuruo T. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J Med Chem 1997; 40: 2047-2052.
83. Lampidis TJ, Kolonias D, Podona T, et al. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry 1997; 36: 2679-2685.
84. Klopman G, Shi LM, Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 1997; 52: 323-334.
85. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1997; 1361: 159-168.
86. Thimmaiah KN, Jayashree BS, Germain GS, Houghton PJ, Horton JK. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells. Oncol Res 1998; 10: 29-41.
87. Bois F, Beney C, Boumendjel A, Mariotte AM, Conseil G, di Pietro A. Halogenated chalcones with high-affinity binding to Pglycoprotein: potential modulators of multidrug resistance. J Med Chem 1998; 41: 4161-4164.
88. Berger D, Citarella R, Dutia M, et al. Novel multidrug resistance reversal agents. J Med Chem 1999; 42: 2145-2161.
89. Ferte J, Kuhnel JM, Chapuis G, Rolland Y, Lewin G, Schwaller MA. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. J Med Chem 1999; 42: 478-489.
90. Osterberg T, Norinder U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10: 295-303.
91. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28: 203-228.
92. Corea G, Fattorusso E, Lanzotti V, et al. Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem 2003; 46: 3395-3402.
93. Choi CH, Kim JH, Kim SH. Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 2004; 320: 672-679.
94. Wang YH, Li Y, Yang SL, Yang L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 2005; 45: 750-757.
95. Voigt B, Coburger C, Monar J, Hilgeroth A. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as Pglycoprotein inhibitors. Bioorg Med Chem 2007; 15: 5110-5113.
96. Coburger C, Wollmann J, Baumert C, et al. Novel insight in structure- activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes. J Med Chem 2008; 51: 5871-5874.
97. Fong WF, Shen XL, Globisch C, et al. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg Med Chem 2008; 16: 3694-3703.
98. Hammann F, Gutmann H, Jecklin U, Maunz A, Helma C, Drewe J. Development of decision tree models for substrates, inhibitors, and inducers of p-glycoprotein. Curr Drug Metab 2009; 10: 339-346.
99. Chan KF, Zhao Y, Chow TW, et al. Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure- activity relationships. ChemMedChem 2009; 4: 594-614.
100. Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO. A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem Pharm Bull (Tokyo) 2010; 58: 1187-1194.
101. Broccatelli F, Carosati E, Neri A, et al. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011; 54: 1740-1751.
102. Perkins R, Fang H, Tong W, Welsh WJ. Quantitative structureactivity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003; 22: 1666-1679.
103. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46: 308-316.
104. Puzyn T, Leszczynski J, Cronin MT. Multiple regression, principal components analysis, cluster analysis, and partial-least squares New York 2009.
105. Kubinyi H. Strategies and recent technologies in drug discovery. Pharmazie 1995; 50: 647-662.
106. Ha SN, Hochman J, Sheridan RP. Mini review on molecular modeling of P-glycoprotein (Pgp). Curr Top Med Chem 2007; 7: 1525-1529.
107. Fernandez M, Caballero J, Fernandez L, Sarai A. Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM). Mol Divers 2010; 15: 269-289.
108. Stouch TR, Gudmundsson O. Progress in understanding the structure- activity relationships of P-glycoprotein. Adv Drug Deliv Rev 2002; 54: 315-328.
109. Ecker G, Chiba P. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Wien Klin Wochenschr 1995; 107: 681-686.
110. Cianchetta G, Singleton RW, Zhang M, et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRINDbased 3D-QSAR. J Med Chem 2005; 48: 2927-2935.
111. Myint KZ, Xie XQ. Recent advances in fragment-based QSAR and multi-dimensional QSAR methods. Int J Mol Sci 2010; 11: 3846-3866.
112. Wiese M, Pajeva IK. Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol. Pharmazie 1997; 52: 679-685.
113. Pajeva I, Wiese M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem 1998; 41: 1815-1826.
114. Cortes-Selva F, Campillo M, Reyes CP, et al. SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrugresistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter. J Med Chem 2004; 47: 576-587.
115. Raad I, Terreux R, Richomme P, et al. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorg Med Chem 2006; 14: 6979-6987.
116. Reyes CP, Munoz-Martinez F, Torrecillas IR, et al. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-betaagarofuran sesquiterpenes as modulators of P-glycoproteindependent multidrug resistance. J Med Chem 2007; 50: 4808-4817.
117. Muller H, Pajeva IK, Globisch C, Wiese M. Functional assay and structure-activity relationships of new third-generation Pglycoprotein inhibitors. Bioorg Med Chem 2008; 16: 2448-2462.
118. Gadhe CG, Madhavan T, Kothandan G, Cho SJ. In Silico Quantitative Structure-Activity Relationship Studies on P-gp Modulators of Tetrahydroisoquinoline-Ethyl-Phenylamine Series. BMC Struct Biol 2011; 11: 5.
119. Kothandan G, Gadhe CG, Madhavan T, Choi CH, Cho SJ. Docking and 3D-QSAR (Quantitative Structure Activity Relationship) Studies of Flavones, the Potent Inhibitors of p-Glycoprotein Targeting the Nucleotide Binding Domain. European Journal of Medicinal Chemistry 2011; In Press.
120. Seelig A. A general pattern for substrate recognition by Pglycoprotein. Eur J Biochem 1998; 251: 252-261.
121. Garrigues A, Loiseau N, Delaforge M, et al. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol Pharmacol 2002; 62: 1288-1298.
122. Ekins S, Kim RB, Leake BF, et al. Application of threedimensional quantitative structure-activity relationships of Pglycoprotein inhibitors and substrates. Mol Pharmacol 2002; 61: 974-981.
123. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 2002; 45: 1737-1740.
124. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.
125. Pajeva IK, Globisch C, Wiese M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem 2009; 4: 1883-1896.
126. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX. New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of P-Glycoprotein Inhibitors. Chem Biol Drug Des 2011; 78: 57-72.
127. Ferreira RJ, Dos Santos DJ, Ferreira MJ, Guedes RC. Toward a Better Pharmacophore Description of P-Glycoprotein Modulators, Based on Macrocyclic Diterpenes from Euphorbia Species. J Chem Inf Model 2011; 51: 1315-1324.
128. Langer T, Eder M, Hoffmann RD, Chiba P, Ecker GF. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 2004; 337: 317-327.
129. Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 2001; 8: 685-713.
130. Lipinski CA. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 2003; 8: 12-16.
131. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 2004; 93: 957-968.
132. Klepsch F, Ecker GF. Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design Molecular Informatics 2010; 29: 276-286.
133. Taylor AM, Storm J, Soceneantu L, et al. Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 2001; 134: 1609-1618.